The effect of iron depletion on chronic hepatitis C virus infection

Increasing evidence exists that iron overload, a common finding in chronic hepatitis C virus (HCV) infection, plays an important role in the pathophysiology of this disease. The mechanisms by which iron excess induces liver damage along with the benefit of iron depletion via phlebotomy on biochemical and histological outcomes in patients with chronic HCV infection have been discussed in this review. Finally, we focus on the effect of iron reduction on the rate of response to interferon antiviral therapy.

• Publication year

  2008

• Venue

  Hepatology International

• Publication date

  2008-05-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12072-008-9076-zPMID 19669262PMCID 2716881
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C.

  2008cited by this paper
• Phlebotomy Improves Therapeutic Response to Interferon in Patients with Chronic Hepatitis C: A Meta-Analysis of Six Prospective Randomized Controlled Trials

  2008cited by this paper
• Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C

  2007cited by this paper
• Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis.

  2007cited by this paper
• Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C

  2007cited by this paper
• Effect of iron depletion on serum markers of fibrogenesis, oxidative stress and serum liver enzymes in chronic hepatitis C: results of a pilot study

  2007cited by this paper
• Molecular mechanism of iron metabolism and overload in chronic hepatitis C

  2007cited by this paper
• Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study

  2007cited by this paper
• Iron reduction therapy by phlebotomy reduces lipid peroxidation and oxidative stress in patients with chronic hepatitis C

  2006cited by this paper
• Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.

  2006cited by this paper
• Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis.

  2005cited by this paper
• Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan

  2005cited by this paper
• Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C.

  2005cited by this paper
• Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course.

  2005cited by this paper
• Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection

  2005cited by this paper
• Iron Accumulation in Chronic Hepatitis C

  2005cited by this paper
• Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C

  2004cited by this paper
• A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan

  2004cited by this paper
• Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.

  2004cited by this paper
• Iron depletion and response to interferon in chronic hepatitis C.

  2003cited by this paper
• HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.

  2003cited by this paper
• Hepatitis C, iron status, and disease severity: relationship with HFE mutations.

  2003cited by this paper
• Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype

  2003cited by this paper
• Hemochromatosis gene modifies course of hepatitis C viral infection.

  2003cited by this paper
• [HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis].

  2003cited by this paper
• Iron as a cofactor in chronic hepatitis C infection.

  2002cited by this paper
• Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection.

  2002cited by this paper
• Iron as a comorbid factor in chronic viral hepatitis

  2002cited by this paper
• Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C

  2002cited by this paper
• Iron in hepatitis C: villain or innocent bystander?

  2002cited by this paper
• Iron, hepatic stellate cells and fibrosis in chronic hepatitis C

  2002cited by this paper
• The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C

  2002cited by this paper
• Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study

  2002cited by this paper
• Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1–derived reactive oxygen species

  2002cited by this paper
• Hepatic Iron Concentration Does Not Influence Response to Therapy with Interferon Plus Ribavirin in Chronic HCV Infection

  2002cited by this paper
• Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C.

  2002cited by this paper
• Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet.

  2001cited by this paper
• Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome.

  2001cited by this paper
• Hepatitis C virus infection.

  2001cited by this paper
• Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial

  2000cited by this paper
• Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial

  2000cited by this paper
• C282Y mutation and hepatic iron status in hepatitis C and cryptogenic cirrhosis.

  2000cited by this paper
• Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis

  2000cited by this paper
• Heterozygosity for the hemochromatosis gene in liver diseases--prevalence and effects on liver histology.

  2000cited by this paper
• Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C

  2000cited by this paper
• Iron enhances hepatitis C virus replication in cultured human hepatocytes.

  2000cited by this paper
• Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations.

  2000cited by this paper
• The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C.

  1999cited by this paper
• A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon

  1999cited by this paper
• Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to interferon therapy

  1999cited by this paper
• Are Haemochromatosis Mutations Related to the Severity of Liver Disease in Hepatitis C Virus Infection?

  1999cited by this paper
• A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.

  1998cited by this paper
• A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C

  1998cited by this paper
• Hepatic iron overload in patients with chronic viral hepatitis: Role of HFE gene mutations

  1998cited by this paper
• Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C

  1998cited by this paper
• Therapy of hepatitis C: Other options

  1997cited by this paper
• Iron and chronic viral hepatitis

  1997cited by this paper
• Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy.

  1997cited by this paper
• Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy.

  1996cited by this paper
• Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C.

  1995cited by this paper
• Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.

  1995cited by this paper
• Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy.

  1995cited by this paper
• Response to interferon alpha therapy is influenced by the iron content of the liver.

  1994cited by this paper
• Response to interferon α therapy is influenced by the iron content of the liver

  1994cited by this paper
• Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron.

  1994cited by this paper
• Measurements of iron status in patients with chronic hepatitis.

  1992cited by this paper

• The Potential Value of Red Cell Distribution Width in Predicting the Transition from Compensated into Decompensated Liver Cirrhosis

  2024cites this paper
• The Role of Red Cell Distribution Width as a Prognostic Marker in Chronic Liver Disease: A Literature Review

  2023cites this paper
• Iron-Induced Hepatocarcinogenesis—Preventive Effects of Nutrients

  2022cites this paper
• Coronavirus disease 2019 (COVID‐19) update: From metabolic reprogramming to immunometabolism

  2022cites this paper
• Cardiovascular Benefits for Blood Donors? A Systematic Review.

  2022cites this paper
• Iron at the Interface of Hepatocellular Carcinoma

  2021cites this paper
• Metabolic reprogramming and immune regulation in viral diseases

  2021cites this paper
• Hyperferritinemia—A Clinical Overview

  2021cites this paper
• HFE Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary Hemochromatosis

  2021cites this paper
• STUDY OF HEPCIDIN LEVEL IN EGYPTIAN HCV INFECTED PATIENTS AND ITS CORRELATION TO IRON AND TOTAL IRON BINDING CAPACITY

  2020influential citation
• Viral eradication restores normal iron status in chronic hepatitis C patients with abnormal iron studies.

  2020cites this paper
• Two cases of hepatopathy and hyperferraemia managed with deferoxamine and phlebotomy

  2019cites this paper
• OsHV-1 infection leads to mollusc tissue lesion and iron redistribution, revealing a strategy of iron limitation against pathogen.

  2019cites this paper
• Serum ferritin in neonatal cholestasis: A specific and active molecule or a non-specific bystander marker?

  2019cites this paper
• The role of iron in hepatic inflammation and hepatocellular carcinoma

  2019cites this paper
• Post-transfusion hepatitis C virus infection among β-thalassaemic individuals with associated clinical parameters

  2018cites this paper
• When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?

  2018cites this paper
• Can Serum Iron Parameters Represent Surrogate Markers for Chronic Hepatitis C-Based Hepatocellular Carcinoma?

  2018cites this paper
• Hemochromatosis: pathophysiology, evaluation, and management of hepatic iron overload with a focus on MRI

  2018cites this paper
• Hemochromatosis and Iron Storage Disorders

  2017cites this paper
• Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution

  2017cites this paper
• Normalizing serum hepcidin but not α-1-antitrypsin level during effective treatment of chronic hepatitis C

  2017cites this paper
• Natural history of chronic hepatitis C development and progression as a consequence of iron and HFE or TfR1 mutations

  2017cites this paper
• Haemochromatosis.

  2016cites this paper
• Serum Ferritin and Transferrin as Biomarkers for Liver Fibrosis Appreciated using Transient Hepatic Elastography ( TE ) by Fibro Scan in Egyptian Patients with Chronic Hepatitis C Virus

  2016cites this paper
• Incidence of hepatocellular carcinoma reduced by phlebotomy treatment in patients with chronic hepatitis C.

  2015cites this paper
• Abnormal serum iron markers in chronic hepatitis B virus infection may be because of liver injury

  2015cites this paper
• Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.

  2015cites this paper
• Review article: management of chronic hepatitis C in patients with contraindications to anti‐viral therapy

  2014cites this paper
• Quantification of liver iron with MRI: State of the art and remaining challenges

  2014cites this paper
• Spike‐in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic iron overload

  2014cites this paper
• Role of Oxidative Stress in Hepatitis B and C Virus

  2014cites this paper
• Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients

  2014cites this paper
• Biochemical nutritional profile of liver cirrhosis patients with hepatocellular carcinoma.

  2014cites this paper
• Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B

  2014cites this paper
• Association between inherited monogenic liver disorders and chronic hepatitis C.

  2014cites this paper
• Anaemia, iron deficiency and susceptibility to infections.

  2014cites this paper
• Serum Iron Markers in Patients With Chronic Hepatitis C Infection

  2013cites this paper
• Sa1025 Hepcidin and Chronic Hepatitis C Virus: Exploring the Controversy

  2013influential citation
• Regulation of iron metabolism during liver injury

  2013cites this paper
• 5 Iron , Oxidative Stress and Health

  2012cites this paper
• Iron, Oxidative Stress and Health

  2012cites this paper
• Review article: the iron overload syndromes

  2012cites this paper
• Iron Status Predicts Malaria Risk in Malawian Preschool Children

  2012cites this paper
• Low Dose Ribavirin for Treatment of Hepatitis C Virus Infected Thalassemia Major Patients; New Indications for Combination Therapy

  2012cites this paper
• Trace metal imbalance associated with oxidative stress and inflammatory status in anti-hepatitis C virus antibody positive subjects.

  2012cites this paper
• New rat models of iron sucrose-induced iron overload

  2011cites this paper
• Hepatitis C virus, oxidative stress and steatosis: current status and perspectives.

  2011cites this paper
• Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

  2011cites this paper
• [108th Scientific Meeting of the Japanese Society of Internal Medicine: invited lecture: 2. Iron metabolism and iron overload].

  2011cites this paper
• A novel monoclonal antibody immunoassay for the detection of human serum hepcidin

  2011cites this paper
• LITHUANIAN UNIVERSITY OF HEALTH SCIENCES MEDICAL ACADEMY

  2011cites this paper
• Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes.

  2011influential citation
• Gender Difference of Alanine Aminotransferase Elevation May Be Associated with Higher Hemoglobin Levels among Male Adolescents

  2010cites this paper
• Effect of angiotensin II on iron-transporting protein expression and subsequent intracellular labile iron concentration in human glomerular endothelial cells

  2010cites this paper
• WITHDRAWN: Low dose ribavirin for treatment of HCV infected thalassemia major patients: New indications for combination therapy.

  2010cites this paper
• Insulin resistance and iron perturbation in patients with chronic hepatitis C

  2010cites this paper
• Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples

  2010cites this paper